Heart-carotid pulse-wave velocity via laser-Doppler vibrometry as a biomarker for arterial stiffening: a feasibility

Simeon Beeckman1, Smriti Badhwar2, Yanlu Li3

  • 1Simeon Beeckman and Patrick Segers are with IBiTech-BioMMedA, Ghent University, Ghent, Belgium.

PubMed

Insights

Laser Doppler vibrometry (LDV) shows promise for measuring heart-carotid pulse-transit time (hcPTT), a new biomarker for arterial stiffness. This method includes the ascending aorta, offering a more comprehensive assessment of cardiovascular risk.

Area of Science:

  • Cardiovascular research
  • Biomedical engineering
  • Medical diagnostics

Background:

  • Large artery stiffening increases cardiovascular risk and organ damage.
  • Pulse-wave velocity (PWV) is a key biomarker for arterial stiffness.
  • Previous work established laser Doppler vibrometry (LDV) for carotid-femoral PWV (cfPWV) measurement.

Purpose of the Study:

  • To assess the feasibility of using an LDV prototype to measure heart-carotid pulse-transit time (hcPTT).
  • To establish hcPTT as a precursor to heart-carotid PWV (hcPWV) measurement.
  • To evaluate hcPTT's potential to include the ascending aorta in arterial stiffness assessment.

Main Methods:

  • Simultaneous signal acquisition from the chest and carotid artery in 100 patients.
  • Utilizing fiducial points: second heart sound (S2) from the heart signal and foot/dicrotic notch (DN) from the carotid waveform.
  • Evaluating four distinct hcPTT estimations based on two heart signal sites.

Main Results:

  • hcPTT estimations showed convincing correlations with established arterial stiffness determinants like age (ρ=0.377).
  • Combining S2 from the heart base with carotid DN yielded the most significant correlations.
  • The LDV method demonstrated feasibility for hcPTT inference in approximately 94% of measurements.

Conclusions:

  • LDV is a feasible tool for inferring hcPTT, a potential new biomarker for arterial stiffness.
  • This method offers a non-invasive approach to assess arterial stiffness, including the ascending aorta.
  • LDV-derived hcPTT may serve as a valuable corollary biomarker for early cardiovascular risk detection.